Unpacking Q1 Earnings: Hims & Hers Health (NYSE:HIMS) In The Context Of Other Healthcare Technology Stocks

HIMS Cover Image
Unpacking Q1 Earnings: Hims & Hers Health (NYSE:HIMS) In The Context Of Other Healthcare Technology Stocks

In This Article:

Looking back on healthcare technology stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Hims & Hers Health (NYSE:HIMS) and its peers.

Healthcare Technology

The 8 healthcare technology stocks we track reported a mixed Q1. As a group, revenues beat analysts’ consensus estimates by 4.4% while next quarter’s revenue guidance was 1% below.

Thankfully, share prices of the companies have been resilient as they are up 6.9% on average since the latest earnings results.

Hims & Hers Health (NYSE:HIMS)

Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products.

Hims & Hers Health reported revenues of $586 million, up 111% year on year. This print exceeded analysts’ expectations by 8.3%. Overall, it was a strong quarter for the company with a solid beat of analysts’ EPS estimates and full-year EBITDA guidance beating analysts’ expectations.

“We’re starting 2025 with incredible momentum. Millions of people are turning to us for access to care that is personal, affordable, and has the potential to drive better outcomes,” said Andrew Dudum, co-founder and CEO.

Hims & Hers Health Total Revenue
Hims & Hers Health Total Revenue

Hims & Hers Health achieved the biggest analyst estimates beat, fastest revenue growth, and highest full-year guidance raise of the whole group. The company added 137,000 customers to reach a total of 2.37 million. Unsurprisingly, the stock is up 45.4% since reporting and currently trades at $60.99.

We think Hims & Hers Health is a good business, but is it a buy today? Read our full report here, it’s free.

Best Q1: Premier (NASDAQ:PINC)

Operating one of the largest healthcare group purchasing organizations in the United States with over 4,350 hospital members, Premier (NASDAQ:PINC) is a technology-driven healthcare improvement company that helps hospitals, health systems, and other providers reduce costs and improve clinical outcomes.

Premier reported revenues of $261.4 million, down 8.9% year on year, outperforming analysts’ expectations by 7.4%. The business had a very strong quarter with an impressive beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

Premier Total Revenue
Premier Total Revenue

The market seems happy with the results as the stock is up 9.1% since reporting. It currently trades at $22.40.

Is now the time to buy Premier? Access our full analysis of the earnings results here, it’s free.

Weakest Q1: Astrana Health (NASDAQ:ASTH)

Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ:ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models.